Format

Send to

Choose Destination
Cell Stem Cell. 2017 Nov 2;21(5):569-573. doi: 10.1016/j.stem.2017.09.014.

Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era.

Author information

1
Department of Clinical Neuroscience and Cambridge Stem Cell Institute, Forvie Site, Cambridge CB2 0PY, UK.
2
Developmental and Regenerative Neurobiology, Wallenberg Neuroscience Center, and Lund Stem Cell Centre, Department of Experimental Medical Science, Lund University, 22184, Lund, Sweden. Electronic address: malin.parmar@med.lu.se.
3
Developmental Biology, The Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA.
4
Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 606-8507, Kyoto, Japan.

Abstract

Stem cell-based therapies for Parkinson's disease are moving into a new and exciting era, with several groups pursuing clinical trials with pluripotent stem cell (PSC)-derived dopamine neurons. As many groups have ongoing or completed GMP-level cell manufacturing, we highlight key clinical translation considerations from our recent fourth GForce-PD meeting.

PMID:
29100010
DOI:
10.1016/j.stem.2017.09.014
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center